Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.
Pfizer said Array’s pipeline, which includes BRAF/MEK inhibitors, will strengthen its own oncology offerings and provide the opportunity for additional growth.
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
Brings total raised in the Series E round to $276 million
Spherix’s investment portfolio into emerging biotech stocks has resulted in substantial gains, turning a roughly $860,000 investment into a position worth more than $11 million at current share price levels, and marking a Price to Book ratio of less than 100%. The recently announced asset-purchase agreement of CBM BioPharma extends pipeline promise.
Zomedica Pharmaceuticals Corp. announced that it has completed its second tranche closing of Series 1 Preferred Shares with the issuance of 7 Series 1 Preferred Shares to an accredited investor under a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share for a total purchase price of $7,000,000.
Under the terms of the deal, a Merck subsidiary is buying all outstanding shares of Tilos for a total of up to $773 million, including an upfront payment and various potential milestone payments.
Government agencies in the United States and U.K. are scrutinizing Roche’s planned acquisition of the gene therapy company.
The bankruptcy announcement comes weeks after Insys founder John Kapoor and four former executives were found guilty of orchestrating a kickback scheme to boost sales of its powerful opioid Subsys.
Global Blood Therapeutics, Inc. announced that on June 1, 2019, the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the company’s common stock with a per share exercise price of $60.78 and restricted stock units for an aggregate of 96,700 shares of the company’s common stock.